[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2014 Analysis of the European Pap Smear/HPV Market

November 2013 | 235 pages | ID: 2B62CBE7E92EN
Venture Planning Group

US$ 2,280.00 US$ 2,850.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Complete report $2,850. DataPack (test volumes, sales forecasts) $1,850.

This report presents a detailed analysis of the Pap Smear/HPV testing market in Europe (France, Germany, Italy, Spain, UK), including clinical significance and current laboratory practice; as well as five-year test volume and sales forecasts by country and market segment.

The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Contains 235 pages and 11 tables
I. INTRODUCTION

II. PAP SMEAR/HPV WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Pap Smear/HPV: Clinical Significance and Laboratory Practices
B. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
      Overview
      ELISA
      Immunofiltration
      Particle-Membrane Capture Immunoassay
      Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
      Chemiluminescence
      Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
    h. Affinity Chromatographu
    e. Liposome Flow-Injection Immunoassay
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
      PCR
      DAP-PCR
      Immuno-PCR
      QC-PCR
      CAR
      DNA
      HPA
      LCR
      NASBA
      QBR
      SDA
    3 SR, and others
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
    a. CT
    b. MRI
    c. NMR
    d. PET
    e. Photonics Spectroscopy
C. Personal Testing

FRANCE: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

GERMANY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

ITALY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

SPAIN: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

U.K.: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. CANCER DIAGNOSTIC PRODUCT SUPPLIERS

Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

LIST OF TABLES

Major Companies Developing or Marketing Pap Smear/HPV Tests
France Pap Smear Test Volume and Diagnostics Sales by Market Segment
France Papillomavirus (HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
Germany Pap Smear Test Volume and Diagnostics Sales by Market Segment
Germany Papillomavirus(HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
Italy Pap Smear Test Volume and Diagnostics Sales by Market Segment
Italy Papillomavirus(HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
Spain Pap Smear Test Volume and Diagnostics Sales by Market Segment
Spain Papillomavirus (HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
U.K. Pap Smear Test Volume and Diagnostics Sales by Market Segment
U.K. Papillomavirus(HPV) Test Volume and Diagnostics Sales Forecast by Market Segment


More Publications